Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print          Annual reports

Friday 09 April, 2021

Alliance Pharma PLC

Posting of Annual Report & Accounts

RNS Number : 9068U
Alliance Pharma PLC
09 April 2021
 

 

 

  9 April 2021

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Posting of Annual Report & Accounts

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Annual Report and Accounts for the year ended 31 December 2020 have now been posted to those shareholders who have opted out of receiving electronic communications from the Group.

 

Printed copies are available by contacting Buchanan by email at [email protected] or by telephoning Buchanan on 020 7466 5000.

 

In addition, and as announced on 29 March 2021, the Annual Report and Accounts for the year ended 31 December 2020 are also   available on the Group's website, www.alliancepharmaceuticals.com  

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

 

Corporate Broking: Patrick Robb

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSBVLLBFZLLBBF

a d v e r t i s e m e n t